In the present study, we tested the hypothesis that deregulation of LSD1 represses prostate cancer progression and evaluated the therapeutic effect of targeting this molecule using a novel selective LSD1 inhibitor, NCL1, originally developed at our institute [19]. Here, KDM1A is linked to prostate cancer.